Graves’ disease is an autoimmune disorder and represents the most prevalent cause of hyperthyroidism. Its pathogenesis involves a complex interplay of immunological mechanisms, with a central role attributed to stimulating autoantibodies directed against the thyroid-stimulating hormone receptor (TSHR) expressed on thyr...
O. Karapanou, Katerina Saltiki, G. Markantes et al.· Drugs in Context· 1 citation
This Review synthesises developments over the past two decades in the epidemiology, natural history, aetiopathogenesis, diagnosis, and management of Hashimoto's thyroiditis, and considers emerging mechanistic insights and approaches to precision medicine that might inform future disease-modifying therapies.
Leonidas H. Duntas, G. Effraimidis· The Lancet Diabetes and Endo...· 0 citations
Thyroid eye disease (TED) is a complex autoimmune disorder and the most common extrathyroidal manifestation of Graves’ disease, characterized by orbital inflammation, tissue remodelling, and varying degrees of functional and cosmetic impairment. Although often mild, moderate-to-severe and sight-threatening forms can si...
G. Markantes, G. Effraimidis, O. Karapanou et al.· Drugs in Context· 1 citation
Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy, representing approximately 2–5% of all thyroid cancers. It develops from the parafollicular C cells of the thyroid gland. Calcitonin, produced by parafollicular C cells, is a highly reliable biomarker for both diagnosis and disease monitoring. MTC commonly...
Katerina Saltiki, O. Karapanou, M. Michalaki et al.· Drugs in Context· 0 citations
INTRODUCTION
Primary thyroid paraganglioma (TPGL) is a rare mimic of medullary thyroid carcinoma (MTC). We report an SDHD-related TPGL caused by a non-canonical splice-region variant.
CASE PRESENTATION
A 36-year-old woman underwent thyroidectomy for a 20 mm EU-TIRADS 4 Bethesda III thyroid nodule with normal serum ca...
G. Effraimidis, V. Trachana, Evmorfia Tzagkaraki et al.· European Thyroid Journal· 0 citations
Direct RNA-level evidence is provided that the intronic SDHD c.314+4A > G variant causes aberrant splicing and supports reclassification from VUS to likely pathogenic under ACMG/AMP criteria and underscore the value of RNA-based assays in interpreting non-canonical splice-site changes.
G. Effraimidis, V. Trachana, Evmorfia Tzagkaraki et al.· European Journal of Endocrin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.